Stern; David M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Stern; David M..The latest application filed is for "transgenic mice over-expressing receptor for advanced glycation endproduct (rage) in brain and uses thereof".

Company Profile

0.33.22

Stern; David M. - Cincinnati OH US
Stern; David M. - Great Neck NY
Stern; David M. - Augusta GA
Stern; David M. - Merion Station PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions for inhibiting ABAD/ABeta protein interaction Grant 8,450,454 - Yan , et al. May 28, 2	2013-05-28
Transgenic Mice Over-expressing Receptor For Advanced Glycation Endproduct (rage) In Brain And Uses Thereof App 20120291145 - Stern; David M. ; et al.	2012-11-15
Rage G82s-related Methods And Compositions For Treating Inflammatory Disorders App 20120128658 - Schmidt; Ann Marie ; et al.	2012-05-24
Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury Grant 8,133,866 - Stern , et al. March 13, 2	2012-03-13
Methods for treating ischemic disorders using carbon monoxide Grant 8,128,963 - Pinsky , et al. March 6, 2	2012-03-06
Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof Grant 8,124,829 - Stern , et al. February 28, 2	2012-02-28
RAGE G82S-related methods and compositions for treating inflammatory disorders Grant 8,067,371 - Schmidt , et al. November 29, 2	2011-11-29
METHODS AND COMPOSITIONS FOR INHIBITING ABAD/ABeta PROTEIN INTERACTION App 20110171194 - Yan; Shi Du ; et al.	2011-07-14
Transgenic Mice Over-Expressing Receptor For Advanced Glycation Endproduct (RAGE) In Brain And Uses Thereof App 20110126298 - Stern; David M. ; et al.	2011-05-26
Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof Grant 7,919,670 - Stern , et al. April 5, 2	2011-04-05
Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury App 20100292134 - Stern; David M. ; et al.	2010-11-18
Method for treating symptoms of diabetes App 20100255081 - Stern; David M. ; et al.	2010-10-07
Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury Grant 7,732,400 - Stern , et al. June 8, 2	2010-06-08
Method for treating symptoms of diabetes Grant 7,700,085 - Stern , et al. April 20, 2	2010-04-20
Rage Fusion Proteins and Methods of Use App 20090060925 - Mjalli; Adnan M.M. ; et al.	2009-03-05
Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof App 20090028882 - Stern; David M. ; et al.	2009-01-29
Methods and Compositions for Inhibiting Abad/Abeta Protein Interaction App 20080274975 - Yan; Shi Du ; et al.	2008-11-06
Methods for Reducing Seizure-Induced Neuronal Damage App 20080260717 - Yan; Shi Du ; et al.	2008-10-23
Methods for treating inflammation App 20080214453 - Stern; David M. ; et al.	2008-09-04
Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury App 20080171701 - Stern; David M. ; et al.	2008-07-17
Rage-related methods for treating inflammation Grant 7,258,857 - Stern , et al. August 21, 2	2007-08-21
Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using analogues of cAMP and cGMP App 20060134073 - Naka; Yoshifumi ; et al.	2006-06-22
Transgenic mice over-expressing ABAD and mutant APP in brain as model of Alzheimer's disease and uses thereof Grant 7,060,870 - Stern , et al. June 13, 2	2006-06-13
RAGE fusion proteins and methods of use App 20060078562 - Mjalli; Adnan M.M. ; et al.	2006-04-13
Intracellular amyloid-beta binding (ERAB) polypeptide-related assays Grant 6,994,974 - Stern , et al. February 7, 2	2006-02-07
Methods for suppressing early growth response--1protein (Egr-1) to reduce vascular injury in a subject Grant 6,969,704 - Pinsky , et al. November 29, 2	2005-11-29
RAGE-related compositions App 20050170382 - Stern, David M. ; et al.	2005-08-04
RAGE G82S-related methods and compositions for treating inflammatory disorders App 20050129682 - Schmidt, Ann Marie ; et al.	2005-06-16
Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof Grant 6,891,081 - Stern , et al. May 10, 2	2005-05-10
Methods for treating ischemic disorders using carbon monoxide App 20050048133 - Pinsky, David J. ; et al.	2005-03-03
Method to increase cerebral blood flow in amyloid angiopathy Grant 6,825,164 - Stern , et al. November 30, 2	2004-11-30
Method for treating symptoms of diabetes App 20040228855 - Stern, David M. ; et al.	2004-11-18
Method for treating symptoms of diabetes Grant 6,790,443 - Stern , et al. September 14, 2	2004-09-14
Endothelial monocyte activating polypeptide II: a mediator which activates host response Grant 6,734,168 - Stern , et al. May 11, 2	2004-05-11
Method to increase cerebral blood flow in amyloid angiopathy Grant 6,677,299 - Stern , et al. January 13, 2	2004-01-13
Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof Grant 6,563,015 - Stern , et al. May 13, 2	2003-05-13
Method For Treating Symptoms Of Diabetes App 20030059423 - STERN, DAVID M. ; et al.	2003-03-27
Endothelial monocyte activating polypeptide II: a mediator which activates host response App 20020160957 - Stern, David M. ; et al.	2002-10-31
Methods for treating inflammation App 20020122799 - Stern, David M. ; et al.	2002-09-05
Method to increase cerebral blood flow in amyloid angiopathy App 20020116725 - Stern, David M. ; et al.	2002-08-22
Intracellular amyloid-beta peptide binding (ERAB) polypeptide Grant 6,268,479 - Stern , et al. July 31, 2	2001-07-31
Endothelial monocyte activating polypeptide II: a mediator which activates host response Grant 6,228,837 - Stern , et al. May 8, 2	2001-05-08
Method of inducing vasorelaxation to treat pulmonary hypertension Grant 5,968,911 - Lawson , et al. October 19, 1	1999-10-19
Antibody which specifically binds to endothelial-monocyte activating polypeptide II Grant 5,641,867 - Stern , et al. June 24, 1	1997-06-24
Solution for prolonged organ preservation Grant 5,552,267 - Stern , et al. September 3, 1	1996-09-03
Error compensating instrument system with digital communications Grant 5,510,779 - Maltby , et al. April 23, 1	1996-04-23
Solution for prolonged organ preservation Grant 5,370,989 - Stern , et al. December 6, 1	1994-12-06
Two-wire compensated level measuring instrument Grant 5,049,878 - Stern * September 17, 1	1991-09-17
Anticoagulant therapy Grant 4,885,277 - Nawroth , et al. December 5, 1	1989-12-05
Two-wire level measuring instrument Grant 4,851,831 - Stern * July 25, 1	1989-07-25
Two-wire level measuring instrument Grant 4,485,673 - Stern December 4, 1	1984-12-04
System and method for obtaining compensated level measurements Grant 4,235,106 - Maltby , et al. November 25, 1	1980-11-25
Matrix Print Rotation Grant 3,814,227 - Hurd, III , et al. June 4, 1	1974-06-04
Quantizing Circuit Correction For Character Recognition Systems Grant 3,599,148 - Stern August 10, 1	1971-08-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.